

Clinical Pharmacology & Therapeutics

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update

Michael A. Martin, James M. Hoffman, Robert R. Freimuth, Teri E. Klein, Betty J. Dong, Munir Pirmohamed, J. Kevin Hicks, Mark R. Wilkinson, David W. Haas and Deanna L. Kroetz

Cite this article as: Michael A. Martin, James M. Hoffman, Robert R. Freimuth, Teri E. Klein, Betty J. Dong, Munir Pirmohamed, J. Kevin Hicks, Mark R. Wilkinson, David W. Haas and Deanna L. Kroetz, Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update, *Clinical Pharmacology & Therapeutics* accepted article preview online 21 February 2014; doi:10.1038/clpt.2014.38

This is a PDF file of an unedited peer-reviewed manuscript that has been accepted for publication. NPG is providing this early version of the manuscript as a service to our customers. The manuscript will undergo copyediting, typesetting and a proof review before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers apply.

Received 02 December 2013; accepted 07 February 2014; Accepted article preview online 21 February 2014

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update

Michael A. Martin¹, James M. Hoffman², Robert R. Freimuth³, Teri E. Klein⁴, Betty J. Dong⁵, Munir Pirmohamed⁶, J. Kevin Hicks⁷, Mark R. Wilkinson², David W. Haas⁸ and Deanna L. Kroetz¹

¹Departments of Bioengineering and Therapeutic Sciences University of California, San Francisco, California USA

²Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA

³Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA

⁴Department of Genetics, Stanford University, Stanford, California USA

⁵Department of Clinical Pharmacy, University of California, San Francisco, California USA

⁶Department of Pharmacology, University of Liverpool, Liverpool UK

⁷Department of Pharmacy and Center for Personalized Healthcare, Cleveland Clinic, Cleveland, OH, USA

⁸Department of Medicine, Vanderbilt University, Nashville, TN USA

Corresponding Author:

Deanna L. Kroetz, Ph.D.
University of California San Francisco
1550 4th St. RH584E
Box 2911
San Francisco, CA 94158-2911
Phone (415) 476-1159
FAX (415) 514-4361

Word Count: 566

References: 6

Key Words: abacavir, HLA-B, pharmacogenetics, CPIC, HIV, AIDS,

The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing was originally published in April 2012. We reviewed recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the supplemental material and included additional resources for applying CPIC guidelines into the electronic health record. Up-to-date information can be found at PharmGKB (<http://www.pharmgkb.org>).

The Clinical Pharmacogenetics Implementation Consortium (CPIC) of the Pharmacogenetics Research Network (<http://www.pgrn.org>) and the Pharmacogenomics Knowledge Base (PharmGKB, <http://www.pharmgkb.org>) provides peer-reviewed, evidence-based, freely accessible genotype-based drug guidelines to help clinicians understand how available genetic test results could be used to optimize drug therapy (1). CPIC guidelines undergo continuous peer review and information that would modify prescribing recommendations pertaining to gene specific alleles and nomenclature are updated periodically on the PharmGKB website. Furthermore, published CPIC guidelines are currently systematically reviewed for updates every two to three years.

The Clinical Pharmacogenetics Implementation Consortium Guidelines for *HLA-B* Genotype and Abacavir Dosing was originally published in April 2012 (2) . To update this guideline, we conducted a focused review of the literature published between April 2011 and November 2013 on *HLA-B* genotype and abacavir use (see Supplemental material on-line). The minor allele frequency table based on ethnicity is already extensive and has not been updated at this time

(Supplemental Tables S1 and S2). The literature review yielded one additional study that we added to the evidence table in the supplement (3) (Supplemental Table S3). We found no new evidence that would change our original recommendations; therefore, the original guideline publication remains current (2). However, recent studies have been published further describing the mechanism by which abacavir can elicit an immune response through *HLA-B*57:01*. Discussion of these studies was added to the supplemental material. Supplemental Figures S1 and S2 also remain unchanged.

Recently, the CPIC Steering Committee recommended that authors address dosing in pediatrics in all updated and new CPIC guidelines. Although much of the evidence linking *HLA-B*57:01* to abacavir hypersensitivity was conducted in adults, there is no reason to suspect that children positive for *HLA-B*57:01* would be at less risk of abacavir hypersensitivity reactions than adults positive for *HLA-B*57:01*. Furthermore, the Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children (Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection; <http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf>) recommends against the use of abacavir in children who test positive for *HLA-B*57:01*.

CPIC guidelines are designed to help clinicians use genetic information to optimize drug therapy, and to do this effectively pharmacogenetic information must be incorporated into electronic health records (EHRs) with clinical decision support (CDS) (4-6). To provide additional resources for applying CPIC guidelines into the EHR, in 2013 CPIC created an informatics working group focused on supporting the adoption of CPIC guidelines within a clinical electronic environment. This guideline is the first to provide these new clinical implementation

resources as part of the supplementary material, which include workflow diagrams that illustrate the storage of a pharmacogenetic result in an EHR and the design of CDS alerts (Supplemental Figures S3 and S4). New tables that correspond to these workflow diagrams are provided that translate genotype test results into an interpreted phenotype (Supplemental Tables S4-S8). These tables provide summary genotype/phenotype terms, example text for documentation in the EHR and point-of-care alerts, and cross-references for drug and gene names to widely-used terminologies and standardized nomenclature systems.

We recognize that each organization and EHR vendor may have different requirements and preferences for implementing pharmacogenetics within a given electronic environment. The intent of these resources is to synthesize foundational knowledge that provides a common starting point for clinical implementation so that individual organizations do not have to create a similar knowledge base for each new gene/drug pair that is implemented. Future CPIC guidelines and guideline updates will provide similar resources to guide the implementation of gene-drug pairs into the EHR with CDS.

Disclaimer

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written, and are intended only to assist clinicians in decision-making, as well as to identify questions for further research. New evidence may have emerged since the time a guideline was submitted for publication. Guidelines are limited in scope and are not applicable to interventions or diseases not specifically identified. Guidelines do not account for all individual variation among patients and cannot be considered inclusive of all proper methods of care or exclusive of

other treatments. It remains the responsibility of the health care provider to determine the best course of treatment for the patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be solely made by the clinician and the patient. CPIC assumes no responsibility for any injury to persons or damage to property related to any use of CPIC's guidelines, or for any errors or omissions.

Acknowledgements

We acknowledge the critical input of members of CPIC of the Pharmacogenomics Research Network (PGRN) particularly Dr. Mary V. Relling and Dr. Kelly E. Caudle (St Jude Children's Research Hospital) and the CPIC informatics working group particularly Dr. Michelle Whirl-Carrillo (Stanford University) and Marc S. Williams (Geisinger Health System). This work was funded by the National Institutes of Health (NIH)/National Institute of General Medical Science (NIH/NIGMS) (PAAR4Kids (U01 GM92666) and PharmGKB (R24 GM61374)). This work is also supported by NIH U01 GM061390 (D.L.K), NIH T32 GM007175 (M.A.M.), NIH/NIGMS U19 GM61388 (R.R.F.), and NIH RO1 AI-077505 (D.W.H.).

Conflict of Interest

T.E.K. is a consultant for Personalis Inc. D.W.H has been a consultant to Merck. The other authors declare no conflicts of interest.

References

- (1) Relling, M.V. & Klein, T.E. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. *Clinical pharmacology and therapeutics* **89**, 464-7 (2011).
- (2) Martin, M.A., Klein, T.E., Dong, B.J., Pirmohamed, M., Haas, D.W. & Kroetz, D.L. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. *Clinical pharmacology and therapeutics* **91**, 734-8 (2012).
- (3) Schnyder, B., Adam, J., Rauch, A., Thurnheer, M.C. & Pichler, W.J. HLA-B*57:01(+) abacavir-naive individuals have specific T cells but no patch test reactivity. *The Journal of allergy and clinical immunology* **132**, 756-8 (2013).
- (4) Shuldiner, A.R. *et al.* The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. *Clinical pharmacology and therapeutics* **94**, 207-10 (2013).
- (5) Wilke, R.A. *et al.* The emerging role of electronic medical records in pharmacogenomics. *Clinical pharmacology and therapeutics* **89**, 379-86 (2011).
- (6) Kullo, I.J., Jarvik, G.P., Manolio, T.A., Williams, M.S. & Roden, D.M. Leveraging the electronic health record to implement genomic medicine. *Genetics in medicine : official journal of the American College of Medical Genetics* **15**, 270-1 (2013).